Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Jazz Pharmaceuticals plc JAZZ

Healthcare
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn... see more

Recent & Breaking News (NDAQ:JAZZ)

Jazz Pharmaceuticals to Present Abstracts from Ongoing Evaluations of Xyrem® (sodium oxybate) at SLEEP 2015

PR Newswire June 4, 2015

Jazz Pharmaceuticals Announces Participation in Two Investor Conferences

PR Newswire May 15, 2015

Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update

Business Wire May 7, 2015

Jazz Pharmaceuticals Announces First Quarter 2015 Financial Results

PR Newswire May 7, 2015

Jazz Pharmaceuticals to Report 2015 First Quarter Financial Results on May 7, 2015

PR Newswire April 23, 2015

Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2014 Financial Results

PR Newswire February 24, 2015

Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March

PR Newswire February 23, 2015

Jazz Pharmaceuticals to Present Data on Defibrotide, an Investigational Treatment, in Patients with Hepatic Veno-Occlusive Disease (VOD) at BMT Tandem Meetings

PR Newswire February 12, 2015

Jazz Pharmaceuticals to Report 2014 Fourth Quarter and Full Year Financial Results on February 24, 2015

PR Newswire February 10, 2015

Jazz Pharmaceuticals to Present at J.P. Morgan Healthcare Conference on January 12

PR Newswire January 5, 2015

Jazz Pharmaceuticals Receives FDA Approval For Intravenous Administration Of Erwinaze® (asparaginase Erwinia chrysanthemi)

PR Newswire December 19, 2014

Jazz Pharmaceuticals Initiates Rolling NDA Submission For Defibrotide For The Treatment Of Severe Hepatic Veno-Occlusive Disease

PR Newswire December 11, 2014

Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update

Business Wire December 9, 2014

Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Trial of Xyrem® (Sodium Oxybate) In Children And Adolescents Who Have Narcolepsy With Cataplexy

PR Newswire December 2, 2014

Jazz Pharmaceuticals To Present New Analysis Of Defibrotide Data In Patients With Hepatic Veno-Occlusive Disease (VOD) At ASH Annual Meeting

PR Newswire December 2, 2014

Jazz Pharmaceuticals Announces Participation in Two Investor Conferences

PR Newswire November 25, 2014

Jazz Pharmaceuticals Announces Participation in Two Investor Conferences

PR Newswire November 6, 2014

Jazz Pharmaceuticals Announces Third Quarter 2014 Financial Results And Updated Guidance

PR Newswire November 4, 2014

Jazz Pharmaceuticals to Report 2014 Third Quarter Financial Results on November 4, 2014

PR Newswire October 21, 2014

Jazz Pharmaceuticals Announces Pricing of $500 Million of Exchangeable Senior Notes

PR Newswire August 8, 2014